Use: Labeled indications
- INDICATIONS AND USAGE: Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
Full indications and usage US FDA label
INDICATIONS AND USAGE: Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure.
Contraindications
CONTRAINDICATIONS: Hypersensitivity to hydralazine, coronary artery disease, mitral valvular rheumatic heart disease.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION: When there is urgent need, therapy in the hospitalized patient may be initiated intramuscularly or as a rapid intravenous bolus injection directly into the vein. Hydralazine Hydrochloride Injection should be used only when the drug cannot be given orally. The usual dose is 20 to 40 mg, repeated as necessary.
Certain patients (especially those with marked renal damage) may require a lower dose. Blood pressure should be checked frequently. It may begin to fall within a few minutes after injection, with the average maximal decrease occurring in 10 to 80 minutes. In cases where there has been increased intracranial pressure, lowering the blood pressure may increase cerebral ischemia.
Most patients can be transferred to oral hydralazine hydrochloride within 24 to 48 hours. The product should be used immediately after the vial is opened. The product should not be added to infusion solutions. Hydralazine Hydrochloride Injection may discolor upon contact with metal; discolored solutions should be discarded.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Dosing: Altered kidney function
Certain patients (especially those with marked renal damage) may require a lower dose.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Solution for injection: 20 mg/mL
- Film-coated tablet: 25 mg, 50 mg
Registered products in the Philippines
13 products registered with the Food and Drug Administration (FDA) Philippines list Hydralazine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Hydralazine HCI (1 product). Products registered under these spellings are included in the table and marked.
All registered products13
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AprezalHydralazine Hydrochloride | 20 mg/mL Solution for Injection (I.M./I.V.)Type I amber colored glass ampoule x 1 mL (Box of 10's) | RxVAT-exempt | Kwality Pharmaceuticals LimitedIndia | Phil Pharmawealth, Inc. | DR-XY40652 | Feb 16, 2027 | |
AprezinHydralazine hydrochloride | 25 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Pharmasant Laboratories Co., Ltd.Thailand | Endure Medical, Inc. | DR-XY36017 | Jun 23, 2027 | |
AprezobasHydralazine Hydrochloride | 20 mg/mL Solution for Injection (IM/IV)In 1 mL Clear, Colorless USP Type I Glass Ampoule (Box of 10's) | RxVAT-exempt | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-9972 | Mar 12, 2031 | |
CardiwonHydralazine Hydrochloride | 20 mg/mL Solution for Injection (IM/IV)USP Type I Amber Glass Ampoule x 1mL in a plastic tray x 10's (Box of 10's) Box of 10's | RxVAT-exempt | Nitin Lifesciences Ltd.India | Seapharma International, Inc. | DRP-6668 | Apr 27, 2031 | |
H-WellHydralazine hydrochloride | 20 mg/mL Solution for Injection (IM/IV)USP Type I Amber glass ampoule x 1 mL (Box of 10's) | RxVAT-exempt | Pharmax India Private LimitedIndia | Wellchem Pharmaceutical Products | DRP-16852 | Jul 18, 2030 | |
HydralexHydralazine hydrochloride | 20 mg/mL Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 1 mL (Box of 10's) | RxVAT-exempt | Farbe Firma Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-14599 | Oct 25, 2028 | |
20 mg/mL Solution For Injection (IM/IV)Type I Amber Glass Ampoule in PVC Tray x 1 mL (Box of 5's and 10's) | Rx | Althea Pharma Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-19022 | Oct 19, 2031 | ||
HyperzineHydralazine hydrochloride | 20 mg/mL Solution for Injection (IM/IV)1 mL USP Type 1 amber colored glass ampoule (Box of 10's) | RxVAT-exempt | Medchem International LimitedIndia | Pharma-Surrey International, Inc. | DRP-4130 | Dec 3, 2027 | |
NoneHydralazine Hydrochloride | 50 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DR-XY24589 | Oct 6, 2028 | |
SapharinHydralazine Hydrochloride | 20 mg/mL Solution for Injection (IM/IV)1 mL USP Type I amber ampoule with purple ring in transparent plastic tray (Box of 10's) | RxVAT-exempt | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc. | DRP-11246 | Feb 21, 2027 | |
Saphdrazin-B20Hydralazine hydrochloride | 20 mg/mL Solution For Injection (IM/IV)Type I Amber Glass Ampoule x 1 mL (Box of 5's and 10's) | RxVAT-exempt | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-18961 | Oct 7, 2031 | |
ZinlonHydralazine Hydrochloride | 20 mg/mL Solution for Injection (I.M/I.V.)USP Type I Amber Glass Ampoule (Box of 10's) | RxVAT-exempt | Norris Medicines LimitedGujarat India | Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Private Limited | DRP-4780-01 | Aug 11, 2031 | |
(no brand name)Hydralazine Hydrochloride | 20 mg/mL Solution for InjectionType I Amber Colored Ampoule x 1 mL (Box of 10's) | RxVAT-exempt | Ciron Drugs & Pharmaceuticals Pvt. LimitedIndia | Phil Pharmawealth, Inc. | DR-XY26260 | Mar 26, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS: In a few patients, hydralazine may produce a clinical picture simulating systemic lupus erythematosus including glomerulonephritis. In such patients, hydralazine should be discontinued unless the benefit-to-risk determination requires continued antihypertensive therapy with this drug. Symptoms and signs usually regress when the drug is discontinued but residua have been detected many years later. Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests).
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS: To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Adverse reactions with hydralazine hydrochloride are usually reversible when dosage is reduced. However, in some cases it may be necessary to discontinue the drug. The following adverse reactions have been observed, but there has not been enough systematic collection of data to support an estimate of their frequency.
Common: Headache, anorexia, nausea, vomiting, diarrhea, palpitations, tachycardia, angina pectoris. Less Frequent: Digestive -constipation, paralytic ileus. Cardiovascular -hypotension, paradoxical pressor response, edema. Respiratory -dyspnea. Neurologic -peripheral neuritis, evidenced by paresthesia, numbness, and tingling; dizziness; tremors; muscle cramps, psychotic reactions characterized by depression, disorientation, or anxiety.
Genitourinary -difficulty in urination. Hematologic -blood dyscrasias, consisting of reduction in hemoglobin and red cell count, leukopenia, agranulocytosis, purpura; lymphadenopathy; splenomegaly. Hypersensitive Reactions -rash, urticaria, pruritis, fever, chills, arthralgia, eosinophilia, and, rarely, hepatitis. Other -nasal congestion, flushing, lacrimation, conjunctivitis.
Pharmacokinetics
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY: Although the precise mechanism of action of hydralazine is not fully understood, the major effects are on the cardiovascular system. Hydralazine apparently lowers blood pressure by exerting a peripheral vasodilating effect through a direct relaxation of vascular smooth muscle. Hydralazine, by altering cellular calcium metabolism, interferes with the calcium movements within the vascular smooth muscle that are responsible for initiating or maintaining the contractile state.
The peripheral vasodilating effect of hydralazine results in decreased arterial blood pressure (diastolic more than systolic); decreased peripheral vascular resistance; and an increased heart rate, stroke volume and cardiac output. The preferential dilatation of arterioles, as compared to veins, minimizes postural hypotension and promotes the increase in cardiac output.
Hydralazine usually increases renin activity in plasma presumably as a result of increased secretion of renin by the renal juxtaglomerular cells in response to reflex sympathetic discharge. This increase in renin activity leads to the production of angiotensin II, which then causes stimulation of aldosterone and consequent sodium reabsorption.
Hydralazine also maintains or increases renal and cerebral blood flow. The average maximal decrease in blood pressure usually occurs 10 to 80 minutes after administration of hydralazine hydrochloride injection. No other pharmacokinetic data on hydralazine hydrochloride injection are available.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Hydralazine 20 mg/mL, 1 mL Ampule | ₱18.77–₱180.00Reference ₱27.88 | per ampule | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Hydralazine (as hydrochloride) |
| PNF listing | Oral: 25 mg and 50 mg tablet |
| PNF listing | Inj.: 20 mg/mL, 1 mL ampul (IM, IV) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Hydralazine Hydrochloride · Fresenius Kabi USA, LLC [US FDA-approved label, version 13, October 7, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8223c44a-73a9-4da5-a468-d1d8bdb0bbd6
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .